Sunnyvale, Calif.

Went public 11/29/00 at $7 per share

Filing Range: 5.0 million shares @ $7 to $8

Shares Outstanding: 35.85 million shares

Underwriters: Morgan Stanley Dean Witter/Lehman Brothers/ Robertson Stephens & Co.

Company Counsel: Cooley Godward LLP

Manager Counsel: Skadden, Arps, Slate, Meagher & Flom

Auditor: Ernst & Young LLP

The Company:

Provides intracellular combinatorial biochemistry research services. The company targets treatments for asthma, allergy and cancer.

Venture Backers:

Frazier & Co.

Chase Capital Partners

Johnson & Johnson Development Corp.


Alta Partners

Soros Fund Management LLC

Lombard Investments Inc.

Alta Communications

CenterPoint Venture Partners

Burr Egan Deleage & Co.

J.F. Shea & Co.

Wilson Sonsini Goodrich & Rosati

Financing Rounds:

Number ofRound Amt.

Round # Round DateStage Investors($ thousands)

1 01/23/19975 Early Stage5999.9

2 11/03/19975 Later Stage 8444.0

3 12/04/19986 Later Stage12960.0

4 02/03/20007 Later Stage15000.0


(Data in $ millions)



Total Revenues: 9.0

Net Income: -12.4